Format

Send to

Choose Destination
Br J Cancer. 2014 Jun 10;110(12):2914-22. doi: 10.1038/bjc.2014.229. Epub 2014 May 22.

Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer.

Author information

1
Department of Radiation Oncology, University Hospital/Inselspital Bern and University of Bern, 3010 Bern, Switzerland.
2
Institute for Pathology, University Hospital Basel, 4003 Basel, Switzerland.
3
Institute for Pathology, University Bern, 3010 Bern, Switzerland.
4
Division of General Thoracic Surgery, University Hospital/Inselspital Bern, 3010 Bern, Switzerland.
5
Division of Thoracic Surgery, University Hospital Basel, 4031 Basel, Switzerland.
6
1] Institute for Pathology, University Bern, 3010 Bern, Switzerland [2] Promed Laboratoire Médical, 1723 Marley, Switzerland.
7
1] Institute for Pathology, University Hospital Basel, 4003 Basel, Switzerland [2] Institute for Pathology, University Bern, 3010 Bern, Switzerland.

Abstract

BACKGROUND:

Recently, fibroblast growth factor receptor 1 (FGFR1) was discovered in squamous cell carcinomas (SCC) of the lung with FGFR1 amplification described as a promising predictive marker for anti-FGFR inhibitor treatment. Only few data are available regarding prevalence, prognostic significance and clinico-pathological characteristics of FGFR1-amplified and early-stage non-small cell lung carcinomas (NSCLC). We therefore investigated the FGFR1 gene status in a large number of well-characterised early-stage NSCLC.

METHODS:

FGFR1 gene status was evaluated using a commercially available fluorescent in situ hybridisation (FISH) probe on a tissue microarray (TMA). This TMA harbours 329 resected, formalin-fixed and paraffin-embedded, nodal-negative NSCLC with a UICC stage I-II. The FISH results were correlated with clinico-pathological features and overall survival (OS).

RESULTS:

The prevalence of an FGFR1 amplification was 12.5% (41/329) and was significantly (P<0.0001) higher in squamous cell carcinoma (SCC) (20.7%) than in adenocarcinoma (2.2%) and large cell carcinoma (13%). Multivariate analysis revealed significantly (P=0.0367) worse 5-year OS in patients with an FGFR1-amplified NSCLC.

CONCLUSIONS:

FGFR1 amplification is common in early-stage SCC of the lung and is an independent and adverse prognostic marker. Its potential role as a predictive marker for targeted therapies or adjuvant treatment needs further investigation.

PMID:
24853178
PMCID:
PMC4056052
DOI:
10.1038/bjc.2014.229
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center